Egalet Corp Stock as Institutional Investors Exit

May 25, 2018 - By Clifton Ray

Egalet Corporation (NASDAQ:EGLT) Logo

Sentiment for Egalet Corp (NASDAQ:EGLT)

Egalet Corp (NASDAQ:EGLT) institutional sentiment decreased to 0.47 in Q4 2017. Its down -0.11, from 0.58 in 2017Q3. The ratio worsened, as 14 investment managers increased or started new positions, while 30 reduced and sold stock positions in Egalet Corp. The investment managers in our partner’s database now hold: 13.62 million shares, down from 20.27 million shares in 2017Q3. Also, the number of investment managers holding Egalet Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 17 Increased: 8 New Position: 6.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions. The company has market cap of $25.84 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It currently has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

The stock decreased 1.93% or $0.0096 during the last trading session, reaching $0.4889. About 481,676 shares traded. Egalet Corporation (NASDAQ:EGLT) has declined 87.31% since May 25, 2017 and is downtrending. It has underperformed by 98.86% the S&P500.

Analysts await Egalet Corporation (NASDAQ:EGLT) to report earnings on August, 8. They expect $-0.26 earnings per share, up 75.00 % or $0.78 from last year’s $-1.04 per share. After $-0.26 actual earnings per share reported by Egalet Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Highbridge Capital Management Llc holds 0.06% of its portfolio in Egalet Corporation for 3.51 million shares. Msd Partners L.P. owns 1.04 million shares or 0.05% of their US portfolio. Moreover, Nj State Employees Deferred Compensation Plan has 0.04% invested in the company for 230,000 shares. The Illinois-based Alyeska Investment Group L.P. has invested 0.01% in the stock. Highland Capital Management Lp, a Texas-based fund reported 119,520 shares.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

Ratings analysis reveals 0 of Egalet’s analysts are positive. Out of 2 Wall Street analysts rating Egalet, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $1.5000 while the high is $3.5. The stock’s average target of $1.50 is 206.81% above today’s ($0.4889) share price. EGLT was included in 3 notes of analysts from January 3, 2018. Stifel Nicolaus downgraded Egalet Corporation (NASDAQ:EGLT) on Wednesday, January 3 to “Hold” rating. The rating was maintained by Cantor Fitzgerald on Monday, March 12 with “Buy”. Cantor Fitzgerald downgraded it to “Hold” rating and $1.5000 target in Tuesday, May 8 report.

More recent Egalet Corporation (NASDAQ:EGLT) news were published by: which released: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018. Also published the news titled: “Egalet’s (EGLT) CEO Bob Radie on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.‘s news article titled: “Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and …” with publication date: May 22, 2018 was also an interesting one.

Egalet Corporation (NASDAQ:EGLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: